Context: Visceral adiposity is a strong determinant of GH secretion, and low endogenous GH secretion is associated with increased insulin resistance, a key component of the metabolic syndrome. Increased fat accumulation in skeletal muscle and liver may play an etiological role in the development of insulin resistance and other complications of the metabolic syndrome. Little is known about the role of decreased endogenous GH secretion in the pathogenesis of insulin resistance in obesity.
Objective: To investigate the relationship between intramyocellular lipids (IMCL), intrahepatic lipids, and peak-stimulated GH in premenopausal women with obesity.
Design And Setting: We conducted a cross-sectional study at a clinical translational research center.
Patients: Patients included 21 premenopausal women with obesity (mean body mass index, 34.0 +/- 4.5 kg/m(2)) and 17 normal-weight controls (mean body mass index, 21.9 +/- 2.0 kg/m(2)) of comparable mean age.
Main Outcomes Measures: IMCL and intrahepatic lipids were measured with proton magnetic resonance spectroscopy ((1)H-MRS). Body composition was measured with magnetic resonance imaging. Peak GH was measured after stimulation with GHRH-arginine.
Results: Obese subjects had higher IMCL, intrahepatic lipids, abdominal and thigh fat, and thigh muscle mass compared with normal-weight controls. There were strong inverse associations between peak GH and both IMCL and intrahepatic lipids independent of age and visceral adiposity. There were positive associations between IMCL and intrahepatic lipids with measures of insulin resistance and serum triglycerides.
Conclusion: In premenopausal women with obesity, peak GH is inversely associated with IMCL and intrahepatic lipids independent of age and visceral adiposity. This suggests that low GH may contribute to insulin resistance in obesity through effects on muscle and intrahepatic lipids.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2758723 | PMC |
| http://dx.doi.org/10.1210/jc.2009-0438 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
High taurocholic acid concentration induces ferroptosis by downregulating FTH1 expression in intrahepatic cholestasis of pregnancy.
BMC Pregnancy Childbirth
January 2025
School of Medicine, The International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, 200030, China.
Background: Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder associated with pregnancy and is usually diagnosed based on high serum bile acid. However, the pathogenesis of ICP is unclear. Ferroptosis has been reported as an iron-dependent mechanism of cell death.
View Article and Find Full Text PDFChronological changes in etiology, pathological and imaging findings in primary liver cancer from 2001 to 2020.
Jpn J Clin Oncol
January 2025
Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
Purpose: To achieve a historical perspective, the chronological changes in primary liver cancer over a 20-year period were investigated at a single institution, focusing on shifts in etiology and the impact on imaging and pathological findings using The Liver Imaging Reporting and Data System.
Materials And Methods: A retrospective study of surgically resected primary liver cancer in 680 patients from 2001 to 2020 resulted in 434 patients with 482 nodules being analyzed. Dynamic contrast-enhanced computed tomography imaging and the Liver Imaging Reporting and Data System 2018 classification were employed.
Intrahepatic levels of microbiome-derived hippurate associates with improved metabolic dysfunction-associated steatotic liver disease.
Mol Metab
December 2024
University of Lille, Lille University hospital, 59045, Lille, France; INSERM U1283, CNRS UMR 8199, Institut Pasteur de Lille, 59045, Lille, France; Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, W12 0NN, United Kingdom; The Victor Phillip Dahdaleh Institute of Genomic Medicine, McGill University, Montréal, H3A 0G1, Canada. Electronic address:
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterised by lipid accumulation in the liver and is often associated with obesity and type 2 diabetes. The gut microbiome recently emerged as a significant player in liver metabolism and health. Hippurate, a host-microbial co-metabolite has been associated with human gut microbial gene richness and with metabolic health.
View Article and Find Full Text PDFSirtuin 7 Promotes Alcohol-Associated Liver Injury via Modulating Myeloid Cell Chemokine (C-C Motif) Ligand 2 Secretion through the NF-κB Signaling Pathway.
Am J Pathol
December 2024
The Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province, The Key Laboratory of Model Animals and Stem Cell Biology of Hunan Province, Engineering Research Center of Reproduction and Translational Medicine of Hunan Province, Institute of Interdisciplinary Studies, Hunan Normal University School of Pharmaceutical Science, Changsha, China. Electronic address:
Article Synopsis
- The progression of Alcohol-associated liver disease (ALD) involves increased gut permeability due to ethanol, leading to bacterial products entering the bloodstream and causing liver inflammation and damage.
- The study used mice without the SIRT7 gene in myeloid cells, finding that this knockout reduced liver injury and inflammation caused by alcohol while minimally impacting lipid metabolism.
- Identification of CCL2 as a key target affected by SIRT7 highlights how its knockout hinders macrophage CCL2 secretion and monocyte recruitment, suggesting that targeting SIRT7 could provide new treatment strategies for ALD.
Resmetirom in the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Comprehensive Review of Current Evidence and Therapeutic Potential.
Cureus
November 2024
Gastroenterology, University of Rochester, Rochester, USA.
Article Synopsis
- Resmetirom is a newly FDA-approved drug for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver condition that can lead to cirrhosis and cancer.
- It has been shown to significantly reduce liver fat, improve liver tissue health, and enhance metabolic health, leading to the resolution of non-alcoholic steatohepatitis (NASH) and fibrosis in many patients.
- Although it may cause some gastrointestinal side effects, resmetirom is generally considered safe, and ongoing phase 3 trials will provide more information on its long-term effectiveness and safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!